Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy

AIDS

Volumn 17, Issue SUPPL. 3, 2003, Pages

  Koblavi Dème, Stéphania ^a   Maran, Matthieu ^a   Kabran, Nguessan ^a   Borget, Marie Yolande ^a   Kalou, Mireille ^a   Kestens, Luc ^b   Maurice, Chantal ^a   Sassan Morokro, Madeleine ^a   Ekpini, Ehounou R ^a   Roelsa, Thierry H ^a,c   Chorba, Terence ^a,c   Nkengasong, John N ^a,c  

^a Project RETRO CI Abidjan   (Côte d’Ivoire)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiretroviral therapy; CD38; CD62L; HIV 1; HLA DR; Immune activation; Immune reconstitution; Viral load

Indexed keywords

ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; HLA DR ANTIGEN; LAMIVUDINE; PADGEM PROTEIN; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ANTIGEN DETECTION; ARTICLE; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURVIVAL TIME; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD;

EID: 0042128344     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200317003-00003     Document Type: Article

References (22)

1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997; 337:734-739.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337:725-733.
3. Palella FJ JR, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
4. Viganó A, Saresella M, Rusconi S, Ferrante P, Clerici M. Expression of CD38 on CD8 T-cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Lancet 1998; 352:1905-1906.
5. Kestens L, Vanham G, Vereecken C, Vandenbruaene M, Vercauteren G, Colebunders RL, et al. Selective increase of activation antigens HLA-DR and CD38 on CD4+CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994; 95:436-441.
6. Mocroft A, Bofill M, Lipman M, Medina E, Borthwick N, Timms A, et al. CD8+, CD38+ lymphocyte percent: a useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:158-162.
7. Nkengasong JN, Kestens L, Ghys PD, Koblavi-Deme S, Bile C, Kalou M, et al. Human immunodeficiency virus type 1 (HIV-1) plasma virus load and markers of immune activation among HIV-infected female sex workers with sexually transmitted diseases in Abidjan, Côte d'Ivoire. J Infect Dis 2001; 183:1405-1408.
8. Shapira-Nahor O, Kalinkovich A, Weisman Z, Greenberg Z, Nahmias J, Shapiro M, et al. Increased susceptibility to HIV-1 infection of peripheral blood mononuclear cells from chronically immune-activated individuals. AIDS 1998; 12:1731-1733.
9. Weisman Z, Kalinkovich, Borkow G, Stein M, Greenberg Z, Bentwich Z. Infection by different HIV-1 subtypes (B and C) results in a similar immune activation profile despite distinct immune backgrounds. J Acquir Immune Defic Syndr 1999; 21:157-163.
10. Clerici M, Butto S, Lukwiya M, Saresella M, Declich S, Trabattoni D, et al. Immune activation in Africa is environmentally-driven and is associated with upregulation of CCR5. AIDS 2000; 14:2083-2092.
11. Kassu A, Tsegaye A, Petros B, Wolday D, Hailu E, Tilahun T, et al. Distribution of lymphocyte subsets in healthy human immunodeficiency virus negative adult Ethiopians from two geographic locales. Clin Diagn Lab Immunol 2001; 8:1171-1176.
12. Djomand G, Roels T, Ellerbrock T, Hanson D, Diomande F, Monga B, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cöte d'Ivoire. AIDS 2003; 17 (Suppl 3):S5-S15.
13. Nkengasong JN, Maurice C, Koblavi S, Kalou M, Yavo D, Maran M, et al. Evaluation of HIV serial and parallel serologic testing algorithms in Abidjan, Cöte d'Ivoire. AIDS 1999; 13:109-117.
14. Nkengasong JN, Maurice C, Koblavi S, Kalou M, Yavo D, Wiltor SZ, et al. Field evaluation of a combination of monospecific enzyme-linked immunosorbent assays for type-specific diagnosis of human immunodeficiency virus type 1 (HIV-1) and HIV-2 infections in HIV-seropositive persons in Abidjan, Ivory Coast. J Clin Microbiol 1998; 36:123-127.
15. Prince HE and Jensen ER. Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr 1991; 4:1227-1232.
16. Market ML, Alvarez-McLeod AP, Sempowski GD, Hale LP, Horvatinovich JM, Weinhold KJ, et al. Thymopoiesis in HIV-infected adults after highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2001; 17:1635-1643.
17. Hengel RL, Jones BM, Kennedy MS, Hubbard MR, McDougal JS. Markers of lymphocyte homing distinguish CD4+ T cell subsets that turn over in response to HIV-1 infection in humans. J Immunol 1999; 163:3539-3548.
18. Hengel RL, Jones BM, Kennedy MS, Hubbard MR, McDougal JS. CD4+ T cells programmed to traffic to lymph nodes account for increases in numbers of CD4+ T cells up to 1 year after initiation of highly active antiretroviral therapy for human immunodeficiency virus type 1 infection. J Infect Dis 2001; 184:93-97.
19. Bouscarat F, Levacher M, Landman R, Muffat-Joly M, Girard PM, Saimot AG, et al. Changes in blood CD8+ lymphocyte activation status and plasma HIV RNA levels during antiretroviral therapy. AIDS 1998; 12:1267-1273.
20. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, et al. Positive effects of combined antiretroviral therapy on CD4+T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-116.
21. Bofill M, Mocroft A, Lipman M, Medina E, Borthwick NJ, Sabin CA, et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T-cells predict the decline of CD4+T-cells in HIV-1-infected patients. AIDS 1996; 10:827-834.
22. Oriendi JM, Bloem AC, Borleffs JCC, Folko-Jan W, Machiel de Vos N, Nottet HSLM, et al. Activation and cell cycle antigens in CD4+ and CD8+ T-cells correlate with plasma human immunodeficiency virus (HIV-1) RNA level in HIV-1 infection. J Infect Dis 1998; 178:1279-1287.